Evidence map›Paper›PMID 36555298›Full record

ArticleInternational journal of molecular sciences2022

Dual-Activated Nano-Prodrug for Chemo-Photodynamic Combination Therapy of Breast Cancer.

Ziyao Lu, Gan Xu, Xiaozhen Yang, Shijia Liu, Yang Sun, Li Chen, Qinying Liu, Jianyong Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ziyao LuFujian Provincial Key Laboratory of Tumor Biotherapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
Gan XuNational & Local Joint Biomedical Engineering Research Center on Photodynamic Technologies, College of Chemistry, Fuzhou University, Fuzhou 350108, China.
Xiaozhen YangNational & Local Joint Biomedical Engineering Research Center on Photodynamic Technologies, College of Chemistry, Fuzhou University, Fuzhou 350108, China.
Shijia LiuFujian Provincial Key Laboratory of Tumor Biotherapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
Yang SunFujian Provincial Key Laboratory of Tumor Biotherapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
Li ChenFujian Provincial Key Laboratory of Tumor Biotherapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
Qinying LiuFujian Provincial Key Laboratory of Tumor Biotherapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
Jianyong LiuNational & Local Joint Biomedical Engineering Research Center on Photodynamic Technologies, College of Chemistry, Fuzhou University, Fuzhou 350108, China.ORCID 0000-0003-3349-6623
Fujian Medical University · CNFuzhou University · CN

Funding

Excellent Young Talents Training Plan of Fujian Cancer Hospital 2020YNYQ01Fujian Province Health Care Young and Middle-aged Backbone Talents Training Project 2020GGA015Fujian Provincial Clinical Research Center for Cancer Radiotherapy and Immunotherapy 2020Y2012Fuzhou University Testing Fund of Precious Apparatus No. 2022T041National Natural Science Foundation of China 81873045, 21471033Natural Science Foundation of Fujian Province, China 2020J011118, 2020J011115, 2021J01608, 2020J01440Startup Fund for Scientific Research, Fujian Medical University 2020QH1225
6 · The paper itself

Abstract

Herein, we developed a dual-activated prodrug, BTC, that contains three functional components: a glutathione (GSH)-responsive BODIPY-based photosensitizer with a photoinduced electron transfer (PET) effect between BODIPY and the 2,4-dinitrobenzenesulfonate (DNBS) group, and an ROS-responsive thioketal linker connecting BODIPY and the chemotherapeutic agent camptothecin (CPT). Interestingly, CPT displayed low toxicity because the active site of CPT was modified by the BODIPY-based macrocycle. Additionally, BTC was encapsulated with the amphiphilic polymer DSPE-mPEG

Indexed as

Breast NeoplasmsNanoparticlesPhotochemotherapyProdrugsAnimalsBoron CompoundsCell Line, TumorDinitrofluorobenzeneFemaleHumansMicePhotosensitizing AgentsReactive Oxygen Species2,4-dinitrofluorobenzene sulfonic acid4,4-difluoro-4-bora-3a,4a-diaza-s-indaceneBoron CompoundsDinitrofluorobenzenePhotosensitizing AgentsProdrugsReactive Oxygen Speciesactivationcombination therapynano-prodrugphotodynamic therapyreactive oxygen species

Identifiers

PMID36555298
PMCPMC9779597
OpenAlexW4312123530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.